Health Care · Services-Medical Laboratories · Nasdaq · CIK 1576280 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $144.07Day +0.31%Mkt cap $19.1B1Y +232.6%Off 52W high −17.2%Vol (1Y) 60.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,960 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.6% of sh out |
| Days to cover4.0d |
| 13F net flow (QoQ)+4.09% |
| Top-10 13F concentration40.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.08B |
| Earnings (TTM)-$433.2M |
| Net margin−42.4% |
| ROIC−45.9% |
| Sales growth 3Y29.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+41.1% |
| 1Y+232.6% |
| 3Y+269.2% |
| 5Y+30.8% |
| Since incept. (ann.)+21.1% |
Total return through 2026-07-29 · series begins 2018-10-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)60.8% |
| Ann. volatility (3Y)62.4% |
| Sharpe (1Y)2.26 |
| Sharpe (3Y)1.01 |
| Max drawdown (1Y)−33.0% |
| Max drawdown (3Y)−59.8% |
| Beta (3Y vs SPY)2.03 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 11.6M | $1.1B | 8.71% | +2.1% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.0M | $649M | 5.30% | +24.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8M | $539M | 4.40% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.6M | $520M | 4.24% | new |
| Invesco Ltd. | 4.9M | $457M | 3.73% | −7.0% |
| GOLDMAN SACHS GROUP INC | 4.4M | $410M | 3.35% | +68.8% |
| TWO SIGMA INVESTMENTS, LP | 4.2M | $391M | 3.19% | +94.7% |
| FMR LLC | 4.1M | $380M | 3.10% | +71.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.6% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 12,806,414 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.85 | — | $301.7M | +48.3% |
| 2025-12-31 | 2026-02-19 | — | — | $281.3M | +39.4% |
| 2025-09-30 | 2025-10-29 | −$0.74 | — | $265.2M | +38.5% |
| 2025-06-30 | 2025-07-30 | −$0.80 | — | $232.1M | +30.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
